Hrishikesh Srinagesh, BA, and James Ferrara, MD, DSc, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, discuss the Mount Sinai Acute GvHD International Consortium (MAGIC) algorithm probability (MAP) that combines serum concentrations of two biomarkers (REG3α and ST2) of graft versus host disease (GvHD). Results show that MAP is a more accurate predictor of survival than clinical response after four weeks of treatment and may serve as a novel endpoint in GvHD treatment trials. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
